PL4277628T3 - Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego - Google Patents
Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznegoInfo
- Publication number
- PL4277628T3 PL4277628T3 PL22700096.5T PL22700096T PL4277628T3 PL 4277628 T3 PL4277628 T3 PL 4277628T3 PL 22700096 T PL22700096 T PL 22700096T PL 4277628 T3 PL4277628 T3 PL 4277628T3
- Authority
- PL
- Poland
- Prior art keywords
- tasquinimod
- treatment
- pharmaceutically acceptable
- acceptable salt
- myelodysplastic syndrome
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21152018 | 2021-01-18 | ||
| EP21201509 | 2021-10-07 | ||
| EP21205665 | 2021-10-29 | ||
| PCT/EP2022/050891 WO2022152902A1 (en) | 2021-01-18 | 2022-01-17 | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4277628T3 true PL4277628T3 (pl) | 2026-02-09 |
Family
ID=80034981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22700096.5T PL4277628T3 (pl) | 2021-01-18 | 2022-01-17 | Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240091215A1 (https=) |
| EP (1) | EP4277628B1 (https=) |
| JP (1) | JP7837338B2 (https=) |
| KR (1) | KR20230133317A (https=) |
| AU (1) | AU2022208424A1 (https=) |
| CA (1) | CA3204120A1 (https=) |
| ES (1) | ES3057099T3 (https=) |
| IL (1) | IL304232A (https=) |
| MX (1) | MX2023008016A (https=) |
| PL (1) | PL4277628T3 (https=) |
| WO (1) | WO2022152902A1 (https=) |
| ZA (1) | ZA202307855B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4346773T3 (pl) | 2021-05-25 | 2025-11-03 | Active Biotech Ab | Duża liczba cząstek taskwinimodu i ich zastosowanie |
| WO2024137713A1 (en) * | 2022-12-20 | 2024-06-27 | Constellation Pharmaceuticals, Inc. | Methods for treating lower risk myelodysplastic syndrome |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| SG186430A1 (en) | 2010-07-09 | 2013-01-30 | Active Biotech Ab | Method for manufacturing of quinoline-3-carboxamides |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| EP3711484A1 (en) * | 2013-07-05 | 2020-09-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Soluble cd33 for treating myelodysplastic syndromes (mds) |
| KR20160136323A (ko) * | 2014-02-28 | 2016-11-29 | 인사이트 코포레이션 | 골수형성이상증후군 치료용 jak1 억제제 |
| JP6647287B2 (ja) * | 2014-09-23 | 2020-02-14 | アクティブ バイオテック エイビー | 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド |
| MX379401B (es) * | 2014-11-19 | 2025-03-11 | Active Biotech Ab | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. |
| EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
| EA202090655A1 (ru) * | 2017-10-06 | 2020-12-07 | Тесаро, Инк. | Комбинированные терапевтические средства и их применение |
| JP2019127473A (ja) * | 2018-01-26 | 2019-08-01 | 学校法人同志社 | 多発性硬化症の治療及び／又は予防のための薬剤 |
-
2022
- 2022-01-17 ES ES22700096T patent/ES3057099T3/es active Active
- 2022-01-17 KR KR1020237026973A patent/KR20230133317A/ko active Pending
- 2022-01-17 EP EP22700096.5A patent/EP4277628B1/en active Active
- 2022-01-17 US US18/272,326 patent/US20240091215A1/en active Pending
- 2022-01-17 JP JP2023541564A patent/JP7837338B2/ja active Active
- 2022-01-17 PL PL22700096.5T patent/PL4277628T3/pl unknown
- 2022-01-17 MX MX2023008016A patent/MX2023008016A/es unknown
- 2022-01-17 WO PCT/EP2022/050891 patent/WO2022152902A1/en not_active Ceased
- 2022-01-17 CA CA3204120A patent/CA3204120A1/en active Pending
- 2022-01-17 AU AU2022208424A patent/AU2022208424A1/en active Pending
-
2023
- 2023-07-04 IL IL304232A patent/IL304232A/en unknown
- 2023-08-11 ZA ZA2023/07855A patent/ZA202307855B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3204120A1 (en) | 2022-07-21 |
| EP4277628C0 (en) | 2025-09-24 |
| WO2022152902A1 (en) | 2022-07-21 |
| IL304232A (en) | 2023-09-01 |
| EP4277628A1 (en) | 2023-11-22 |
| AU2022208424A1 (en) | 2023-08-24 |
| JP7837338B2 (ja) | 2026-03-30 |
| KR20230133317A (ko) | 2023-09-19 |
| ZA202307855B (en) | 2025-12-17 |
| JP2024503372A (ja) | 2024-01-25 |
| ES3057099T3 (en) | 2026-02-26 |
| EP4277628B1 (en) | 2025-09-24 |
| AU2022208424A9 (en) | 2024-05-09 |
| US20240091215A1 (en) | 2024-03-21 |
| MX2023008016A (es) | 2023-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3063562T3 (en) | Combination therapy including a kras-g12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| PL3577135T3 (pl) | Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5 | |
| IL190284A (en) | Use of milenzipran, or a suitable pharmaceutical salt, in the preparation of a drug for the treatment of fibromyalgia | |
| HUE067057T2 (hu) | Gyógyszerkészítmény C5-tel kapcsolatos betegség kezelésében vagy megelõzésében történõ alkalmazásra | |
| SI3676285T1 (sl) | Cepivo za uporabo pri profilaksi in/ali zdravljenju bolezni | |
| SG11202011261PA (en) | Urolithin a and derivatives thereof for use in therapy | |
| GB202103211D0 (en) | Pharmaceutical compounds for use in therapy | |
| PL4277628T3 (pl) | Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego | |
| GB2587172B (en) | Pyronaridine or pharmaceutically acceptable salts thereof for the treatment of cancer | |
| MX2019015212A (es) | Compuestos para el tratamiento del sarcoma. | |
| IL236041A (en) | 1- [6 - [[5- (2-Fluoropropyl) -3-methyl-triazole-4-yl] methoxy] -3-pyridyl] imidazole-4-carbonitrile or its common pharmaceutical salt and such compound for use in the treatment of diseases | |
| MX2019015280A (es) | Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias. | |
| IL272562B1 (en) | Compounds or pharmaceutically acceptable salts thereof for the treatment of mycobacterial infection | |
| IL304737A (en) | Dangapetide for the treatment or prevention of kidney disease | |
| LT3697399T (lt) | Terapiniai agentai, skirti panaudoti gydant neramių kojų sindromą | |
| ZA202101652B (en) | Novel thiazole derivatives and pharmaceutically acceptable salts thereof | |
| HK40100349B (zh) | 用於治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐 | |
| HK40100349A (zh) | 用於治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐 | |
| PL4072532T3 (pl) | Postać dawkowania do zastosowania w leczeniu lub zapobieganiu chorobie | |
| PT3937949T (pt) | Fitoecdisonas e seus derivados para utilização no tratamento da alteração da função respiratória | |
| PL4114368T3 (pl) | Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w terapii skojarzonej | |
| IL286029A (en) | Potassium binding agents for use in hemodialysis patients | |
| GB202002299D0 (en) | Agents for use in the treatment of tissue damage | |
| IL310580A (en) | RALOXIFENE for use in the treatment of SARS-COV-2 infections | |
| GB2625845B (en) | Ophiopogonin D for use in the treatment caused by rotavirus infection |